This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Armstrong, S. A. Articles by Look, A. T. Search for Related Content PubMed PubMed Citation Articles by Armstrong, S. A. Articles by Look, A. T. Social Bookmarking                            What's this?

Molecular Genetics of Acute Lymphoblastic Leukemia

Scott A. Armstrong, A. Thomas Look

From the Department of Pediatric Oncology, Dana-Farber Cancer Institute; and the Division of Hematology/Oncology, Children's Hospital, Harvard Medical School, Boston, MA

Address reprint requests to Scott A. Armstrong, MD, PhD, Children's Hospital, Karp Research Labs, Rm 08211, 1 Blackfan Circle, Boston, MA 02115; e-mail: Scott.Armstrong{at}childrens.harvard.edu.

From its beginnings two decades ago with the analysis of chromosomal translocation breakpoints, research into the molecular pathogenesis of acute lymphoblastic leukemia (ALL) has now progressed to the large-scale resequencing of candidate oncogenes and tumor suppressor genes in the genomes of ALL cases blocked at various developmental stages within the B- and T-cell lineages. In this review, we summarize the findings of these investigations and highlight how this information is being integrated into multistep mutagenesis cascades that impact specific signal transduction pathways and synergistically lead to leukemic transformation. Because of these advances, fueled by improved technology for mutational analysis and the development of small-molecule drugs and monoclonal antibodies, the future is bright for a new generation of targeted therapies. Best illustrated by the successful introduction of imatinib mesylate, these new treatments will interfere with disordered molecular pathways specific for the leukemic cells, and thus should exhibit much less toxicity and fewer long-term adverse effects than currently available therapeutic modalities.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				R. K. Slany The molecular biology of mixed lineage leukemia Haematologica, July 1, 2009; 94(7): 984 - 993. [Abstract] [Full Text] [PDF]

				R. Bassan, O. Spinelli, E. Oldani, T. Intermesoli, M. Tosi, B. Peruta, G. Rossi, E. Borlenghi, E. M. Pogliani, E. Terruzzi, et al. Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL) Blood, April 30, 2009; 113(18): 4153 - 4162. [Abstract] [Full Text] [PDF]

				R.T. Williams and C.J. Sherr The INK4-ARF (CDKN2A/B) Locus in Hematopoiesis and BCR-ABL-induced Leukemias Cold Spring Harb Symp Quant Biol, November 26, 2008; (2008) sqb.2008.73.039v2. [Abstract] [PDF]

				N. Kawamata, S. Ogawa, M. Zimmermann, B. Niebuhr, C. Stocking, M. Sanada, K. Hemminki, G. Yamatomo, Y. Nannya, R. Koehler, et al. Cloning of genes involved in chromosomal translocations by high-resolution single nucleotide polymorphism genomic microarray PNAS, August 19, 2008; 105(33): 11921 - 11926. [Abstract] [Full Text] [PDF]

				F. Tucci and M. Arico Treatment of pediatric acute lymphoblastic leukemia Haematologica, August 1, 2008; 93(8): 1124 - 1128. [Full Text] [PDF]

				T. Burmeister, S. Schwartz, C. R. Bartram, N. Gokbuget, D. Hoelzer, and E. Thiel Patients' age and BCR-ABL frequency in adult B-precursor ALL: a retrospective analysis from the GMALL study group Blood, August 1, 2008; 112(3): 918 - 919. [Full Text] [PDF]

				P. Van Vlierberghe, M. van Grotel, J. Tchinda, C. Lee, H. B. Beverloo, P. J. van der Spek, A. Stubbs, J. Cools, K. Nagata, M. Fornerod, et al. The recurrent SET-NUP214 fusion as a new HOXA activation mechanism in pediatric T-cell acute lymphoblastic leukemia Blood, May 1, 2008; 111(9): 4668 - 4680. [Abstract] [Full Text] [PDF]

				B. V. Balgobind, P. Van Vlierberghe, A. M. W. van den Ouweland, H. B. Beverloo, J. N. R. Terlouw-Kromosoeto, E. R. van Wering, D. Reinhardt, M. Horstmann, G. J. L. Kaspers, R. Pieters, et al. Leukemia-associated NF1 inactivation in patients with pediatric T-ALL and AML lacking evidence for neurofibromatosis Blood, April 15, 2008; 111(8): 4322 - 4328. [Abstract] [Full Text] [PDF]

				E. Flex, V. Petrangeli, L. Stella, S. Chiaretti, T. Hornakova, L. Knoops, C. Ariola, V. Fodale, E. Clappier, F. Paoloni, et al. Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia J. Exp. Med., April 14, 2008; 205(4): 751 - 758. [Abstract] [Full Text] [PDF]

				N. Kawamata, S. Ogawa, M. Zimmermann, M. Kato, M. Sanada, K. Hemminki, G. Yamatomo, Y. Nannya, R. Koehler, T. Flohr, et al. Molecular allelokaryotyping of pediatric acute lymphoblastic leukemias by high-resolution single nucleotide polymorphism oligonucleotide genomic microarray Blood, January 15, 2008; 111(2): 776 - 784. [Abstract] [Full Text] [PDF]

				S. Mi, J. Lu, M. Sun, Z. Li, H. Zhang, M. B. Neilly, Y. Wang, Z. Qian, J. Jin, Y. Zhang, et al. MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia PNAS, December 11, 2007; 104(50): 19971 - 19976. [Abstract] [Full Text] [PDF]

				M. Fasseu, P. D. Aplan, M. Chopin, N. Boissel, J.-C. Bories, J. Soulier, H. von Boehmer, F. Sigaux, and A. Regnault p16INK4A tumor suppressor gene expression and CD3{epsilon} deficiency but not pre-TCR deficiency inhibit TAL1-linked T-lineage leukemogenesis Blood, October 1, 2007; 110(7): 2610 - 2619. [Abstract] [Full Text] [PDF]

				C. D. Baldus, P. Martus, T. Burmeister, S. Schwartz, N. Gokbuget, C. D. Bloomfield, D. Hoelzer, E. Thiel, and W. K. Hofmann Low ERG and BAALC Expression Identifies a New Subgroup of Adult Acute T-Lymphoblastic Leukemia With a Highly Favorable Outcome J. Clin. Oncol., August 20, 2007; 25(24): 3739 - 3745. [Abstract] [Full Text] [PDF]

				E. Clappier, W. Cuccuini, A. Kalota, A. Crinquette, J.-M. Cayuela, W. A. Dik, A. W. Langerak, B. Montpellier, B. Nadel, P. Walrafen, et al. The C-MYB locus is involved in chromosomal translocation and genomic duplications in human T-cell acute leukemia (T-ALL), the translocation defining a new T-ALL subtype in very young children Blood, August 15, 2007; 110(4): 1251 - 1261. [Abstract] [Full Text] [PDF]

				A. Souabni, W. Jochum, and M. Busslinger Oncogenic role of Pax5 in the T-lymphoid lineage upon ectopic expression from the immunoglobulin heavy-chain locus Blood, January 1, 2007; 109(1): 281 - 289. [Abstract] [Full Text] [PDF]

				X.-Y. Su, V. Della-Valle, I. Andre-Schmutz, C. Lemercier, I. Radford-Weiss, P. Ballerini, M. Lessard, M. Lafage-Pochitaloff, F. Mugneret, R. Berger, et al. HOX11L2/TLX3 is transcriptionally activated through T-cell regulatory elements downstream of BCL11B as a result of the t(5;14)(q35;q32) Blood, December 15, 2006; 108(13): 4198 - 4201. [Abstract] [Full Text] [PDF]

				P. Van Vlierberghe, M. van Grotel, H. B. Beverloo, C. Lee, T. Helgason, J. Buijs-Gladdines, M. Passier, E. R. van Wering, A. J. P. Veerman, W. A. Kamps, et al. The cryptic chromosomal deletion del(11)(p12p13) as a new activation mechanism of LMO2 in pediatric T-cell acute lymphoblastic leukemia Blood, November 15, 2006; 108(10): 3520 - 3529. [Abstract] [Full Text] [PDF]

				C. D. Baldus, T. Burmeister, P. Martus, S. Schwartz, N. Gokbuget, C. D. Bloomfield, D. Hoelzer, E. Thiel, and W. K. Hofmann High Expression of the ETS Transcription Factor ERG Predicts Adverse Outcome in Acute T-Lymphoblastic Leukemia in Adults J. Clin. Oncol., October 10, 2006; 24(29): 4714 - 4720. [Abstract] [Full Text] [PDF]

				R. T. Williams, M. F. Roussel, and C. J. Sherr Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia PNAS, April 25, 2006; 103(17): 6688 - 6693. [Abstract] [Full Text] [PDF]

				C.-H. Pui and W. E. Evans Treatment of Acute Lymphoblastic Leukemia N. Engl. J. Med., January 12, 2006; 354(2): 166 - 178. [Full Text] [PDF]

				N. Gokbuget and D. Hoelzer Treatment of Adult Acute Lymphoblastic Leukemia Hematology, January 1, 2006; 2006(1): 133 - 141. [Abstract] [Full Text] [PDF]